First-in-class antiviral compound against HSV-1 and HSV-2 acyclovir-resistant strains

Patent number:

EP25382332

Comunidad de Madrid.svg
No items found.

LN-7 is a new endonuclease Inhibitor that prevents Herpes Simplex Virus 1 and 2 (HSV-1 and 2) replication in preclinical in vitro and in vivo studies, postulating as novel antiviral candidate for prevention, conventional antiviral resistant HSV and combination therapy against herpesvirus.

Countries:
Spain
Regions:
Community of Madrid
Centers:
CSIC, UNIVERSIDAD AUTONOMA DE MADRID
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
Applications

• Novel mode of action, different from other antivirals • Prophylactic antiviral effect • Suitable for acyclovir-resistant HSV-1 and HSV-2 • Synergistic activity in combination with acyclovir • Strong candidate for immunocompromised patiens •Safety and efficacy proven in preclinical in vivo models

Comments

Other related patents

Health

IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF BREAST CANCER

Countries
Spain
Know more
Health

DETECTION OF THE RISK OF ORAL DISEASES MEDIATED BY MICROORGANISMS

Countries
Spain
Know more
Health
Food & Agro

Aldoximes as NO donors, and their uses as plant architecture modifiers and in therapy

Countries
Spain
Know more
Get back to patents directory